Miravo Healthcare
6733 Mississauga Road, Suite 800
Mississauga
Ontario
L5N 6J5
Canada
Tel: (905) 876-1118
Website: https://www.miravohealthcare.com/
122 articles about Miravo Healthcare
-
Nuvo Pharmaceuticals to Webcast Live at Life Sciences Investor Forum March 26th
3/23/2020
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Jesse Ledger, Nuvo's President & Chief Executive Officer and Kelly Demerino, Nuvo's Interim Chief Financial Officer will present live at LifeSciencesInvestorForum.com on March 26th.
-
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States
3/4/2020
Nuvo Pharmaceuticals Inc., a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Dr. Reddy's Laboratories Inc. has launched its generic version of Vimovo in the United States.
-
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx™ For The Acute Treatment of Migraine
2/27/2020
Nuvo Pharmaceuticals Inc. announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. has received a Notice of Compliance from Health Canada for Suvexx™.
-
Nuvo Pharmaceuticals Announces 2019 and Fourth Quarter Results
2/25/2020
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and twelve months ended December 31, 2019.
-
Nuvo Pharmaceuticals™ Responds to Market Activity
2/11/2020
At the request of the Investment Industry Regulatory Organization of Canada, Nuvo Pharmaceuticals Inc. wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares.
-
Nuvo Pharmaceuticals Announces Fourth Quarter 2019 Results Release Date and Conference Call Details
2/11/2020
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its fourth quarter 2019 financial results before markets open on Tuesday, February 25, 2020.
-
Nuvo Pharmaceuticals Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty
1/7/2020
The Company has received US$5.6 million to-date.
-
Nuvo Pharmaceuticals Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents
11/11/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United States District Court for the District of New Jersey has denied a motion for summary judgment filed by Dr. Reddy's Laboratories Inc. (DRL)
-
Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results
10/31/2019
Nuvo Pharmaceuticals Inc., a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, announced its financial and operational results for the three and nine months ended September 30, 2019.
-
Nuvo Pharmaceuticals Announces Third Quarter 2019 Results Release Date and Conference Call Details
10/17/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its third quarter 2019 financial results before markets open on Thursday, October 31, 2019.
-
Nuvo Pharmaceuticals Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference
9/9/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that Jesse Ledger, Nuvo's President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City.
-
Nuvo Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
9/4/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that Jesse Ledger, Nuvo's President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019
-
Nuvo Pharmaceuticals Announces 2019 Second Quarter Results
8/14/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and six months ended June 30, 2019
-
Nuvo Pharmaceuticals Announces Second Quarter 2019 Results Release Date and Conference Call Details
7/31/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its second quarter 2019 financial results before markets open on Wednesday, August 14, 2019.
-
Nuvo Pharmaceuticals Provides VIMOVO Patent Update
7/30/2019
The Company has received notice that the United States Court of Appeals (the Court of Appeals) has denied the Company's request to rehear Nuvo's case with respect to the validity of patents 6,926,907 and 8,557,285 (the '907 and '285 Patents) covering speciality pain medicine VIMOVO.
-
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting and Updates to the Facility Agreement with Deerfield
6/26/2019
Nuvo Pharmaceuticals Inc. a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced that at its 2019 Annual Meeting of Shareholders held on June 25, 2019 in Mississauga, all nominees listed in the management proxy circular dated May 16, 2019 were elected as directors of the Company.
-
Nuvo Pharmaceuticals™ Provides Corporate Update
6/17/2019
Nuvo Pharmaceuticals Inc. provided a corporate update on various matters including its VIMOVO patents, the identification of Aralez Transaction synergies and an update regarding the status of its financing arrangements with Deerfield Management Company, L.P..
-
Nuvo Pharmaceuticals Announces that U.S. Court of Appeals for the Federal Circuit Reverses District Court's Decision Related to Certain Vimovo Patents
5/15/2019
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that the United States Court of Appeals for the Federal Circuit reversed the decision by the United States District Court for the District of New Jersey related to certain Vimovo patents
-
Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results
5/14/2019
Nuvo Pharmaceuticals Inc. announced its financial and operational results for the first quarter ended March 31, 2019.
-
Nuvo Pharmaceuticals™ to Present at the Bloom Burton & Co. Healthcare Investor Conference
4/23/2019
Nuvo Pharmaceuticals Inc. announced that Jesse Ledger, the Company's President & Chief Executive Officer will be providing a corporate update at the Bloom Burton & Co Healthcare Investor Conference on Tuesday, April 30th - 2:00 p.m. at the Metro Toronto Convention Centre, 255 Front Street West, Toronto.